Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. The expansion will evaluate the combination of Decoy20 with BeiGene ...
Innovative dispersions leverage HydroGraph’s high-purity graphene technology to enhance electrode conductivityTORONTO, March 18, 2025 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback